Corbus's Tempo I study in second-line oral pharyngeal cancer is designed for accelerated approval based on ORR, with final approval based on OS. The control arm is assumed at an ORR around about the 20%, and a BLA is expected around second half of 28. The CEO says key opinion leaders view an ORR north of 30% as desirable in second line and north of 50 in front line.
CRBP · Corbus Pharmaceuticals Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 49%
- Last earnings
- Nov 15, 2026
- Latest filing
- 10-Q · Nov 10
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Corbus Pharmaceuticals Holdings, Inc. said CRB-913 produced significant mean weight loss at 20 mg, 40 mg and 60 mg; the highest dose achieved 5% after 12 weeks. Adverse-event discontinuation was 8.3%, with no serious or severe psychiatric adverse events.
Corbus Pharmaceuticals Holdings reported that CRB-913’s 60 mg dose achieved mean 5% weight loss at 12 weeks. Nine-month 2026 net loss widened to $95.8 million from $58.0 million, with $115.3 million in cash at September 30, 2026.
Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $37.8 million for Q3 2026 and held $115.3 million in cash, cash equivalents, and investments, expected to fund operations into 2028. CRB-913 achieved 5% mean weight loss after 12 weeks.
Corbus Pharmaceuticals launched a phase three registrational study in second line oral pharyngeal cancer and reported 5% weight loss in three months in a phase 1b obesity trial with about 250 patients.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and investments | $115.3M | as of September 30, 2026 | — |
| net proceeds under the Open Market Sale Agreement | $18.6M | the three months ended September 30, 2026 filing | — |
| research and development expenses recorded in U.K. and Australia subsidiaries | 13% | the three months ended September 30, 2026 filing | — |
| shares of common stock sold under the Open Market Sale Agreement | 1,932,621 | the three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRBP
this stock
Corbus Pharmaceuticals Holdings, Inc.
|
$42.45M | -74.7% | +97.6% | — | 15.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 30
Corbus's Tempo I study in second-line oral pharyngeal cancer is designed for accelerated approval based on ORR, with final approval based on OS. The control arm is assumed at an ORR around about the 20%, and a BLA is expected around second half of 28. The CEO says key opinion leaders view an ORR north of 30% as desirable in second line and north of 50 in front line.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRBP | -39.2% | -49.1% | -72.7% | -51.2% | -74.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -30.7% | -39.9% | -63.5% | -42.5% | -75.9% |